$TRAW
Traws Pharma, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013675 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $57.00K $57.00K $56.00K
YoY Change 0.0% 0.0% -6.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.105M $2.139M $2.074M
YoY Change -7.84% -24.95% 16.52%
% of Gross Profit
Research & Development $3.593M $2.038M $1.745M
YoY Change 103.8% 10.04% -61.48%
% of Gross Profit
Depreciation & Amortization $3.000K $4.000K $4.000K
YoY Change 0.0% -42.86%
% of Gross Profit
Operating Expenses $5.698M $4.177M $3.819M
YoY Change 40.8% -11.17% -39.48%
Operating Profit -$5.641M -$4.120M
YoY Change 41.38% -11.3%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $243.0K $96.00K -$1.000K
YoY Change 3371.43% -838.46% -96.67%
Pretax Income -$5.398M -$4.024M -$3.764M
YoY Change 56.33% -4.89% -41.46%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.398M -$4.024M -$3.764M
YoY Change 56.33% -4.89% -41.46%
Net Earnings / Revenue -9470.18% -7059.65% -6721.43%
Basic Earnings Per Share -$0.26 -$0.19
Diluted Earnings Per Share -$0.26 -$0.19 -$179.8K
COMMON SHARES
Basic Shares Outstanding 20.90M 20.90M 20.89M
Diluted Shares Outstanding 20.92M 20.90M

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.61M $46.53M $55.07M
YoY Change -28.23% 6.46% 189.84%
Cash & Equivalents $42.61M $46.53M $55.07M
Short-Term Investments
Other Short-Term Assets $303.0K $306.0K $35.00K
YoY Change 212.37% 60.21% -80.56%
Inventory
Prepaid Expenses
Receivables $28.00K $28.00K $28.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $43.75M $48.03M $55.43M
YoY Change -27.0% 8.69% 180.18%
LONG-TERM ASSETS
Property, Plant & Equipment $28.00K $31.00K $38.00K
YoY Change -33.33% -31.11% -26.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000K $10.00K $10.00K
YoY Change -91.67% -92.86% -93.33%
Total Long-Term Assets $29.00K $41.00K $48.00K
YoY Change -46.3% -77.84% -76.24%
TOTAL ASSETS
Total Short-Term Assets $43.75M $48.03M $55.43M
Total Long-Term Assets $29.00K $41.00K $48.00K
Total Assets $43.78M $48.07M $55.48M
YoY Change -27.02% 8.33% 177.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.760M $3.003M $2.757M
YoY Change -7.16% -30.0% -42.95%
Accrued Expenses $3.350M $3.231M $3.132M
YoY Change 21.86% 8.31% -36.88%
Deferred Revenue $226.0K $226.0K $226.0K
YoY Change 0.0% 0.0% 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.336M $6.460M $6.115M
YoY Change 4.43% -13.86% -38.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.073M $3.130M $3.243M
YoY Change -6.85% -19.45% -14.66%
Total Long-Term Liabilities $3.073M $3.130M $3.243M
YoY Change -6.85% -19.45% -14.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.336M $6.460M $6.115M
Total Long-Term Liabilities $3.073M $3.130M $3.243M
Total Liabilities $10.41M $9.590M $9.358M
YoY Change 0.82% -15.77% -32.24%
SHAREHOLDERS EQUITY
Retained Earnings -$458.3M -$452.9M -$444.7M
YoY Change 3.93% 3.51% 3.77%
Common Stock $491.7M $491.4M $490.9M
YoY Change 0.22% 4.44% 12.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.37M $38.48M $46.12M
YoY Change
Total Liabilities & Shareholders Equity $43.78M $48.07M $55.48M
YoY Change -27.02% 8.33% 177.58%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$5.398M -$4.024M -$3.764M
YoY Change 56.33% -4.89% -41.46%
Depreciation, Depletion And Amortization $3.000K $4.000K $4.000K
YoY Change 0.0% -42.86%
Cash From Operating Activities -$3.900M -$4.214M -$4.265M
YoY Change -8.6% -2.11% -22.03%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -35.00K
YoY Change -100.0% -100.0% -112.5%
NET CHANGE
Cash From Operating Activities -3.900M -4.214M -4.265M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 0.000 -35.00K
Net Change In Cash -3.900M -4.214M -4.300M
YoY Change -124.88% -1.86% -17.15%
FREE CASH FLOW
Cash From Operating Activities -$3.900M -$4.214M -$4.265M
Capital Expenditures $0.00
Free Cash Flow -$4.265M
YoY Change -22.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8537000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20904085
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15780863
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20904085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15201719
dei Entity Central Index Key
EntityCentralIndexKey
0001130598
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20895563
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20895563
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-fifteen
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36020
dei Entity Registrant Name
EntityRegistrantName
Onconova Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3627252
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Address Address Line1
EntityAddressAddressLine1
12 Penns Trail
dei Entity Address City Or Town
EntityAddressCityOrTown
Newtown
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18940
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
759-3680
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20895563
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
ONTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46533000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55070000
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
28000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444719000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-41000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38484000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
28000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1472000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
48033000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55430000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2022Q2 us-gaap Assets
Assets
48074000
CY2021Q4 us-gaap Assets
Assets
55478000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3003000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2757000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3231000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3132000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6460000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6115000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3130000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3243000
CY2022Q2 us-gaap Liabilities
Liabilities
9590000
CY2021Q4 us-gaap Liabilities
Liabilities
9358000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20895563
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20895563
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
209000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
491181000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
490644000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452865000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46120000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48074000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55478000
CY2022Q2 us-gaap Revenues
Revenues
57000
CY2021Q2 us-gaap Revenues
Revenues
57000
us-gaap Revenues
Revenues
113000
us-gaap Revenues
Revenues
113000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2139000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2850000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4325000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5067000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2038000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1852000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4040000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3789000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4177000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
4702000
us-gaap Operating Expenses
OperatingExpenses
8365000
us-gaap Operating Expenses
OperatingExpenses
8856000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4120000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4645000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8252000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8743000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-427000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
209000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
106000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4024000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-4231000
us-gaap Profit Loss
ProfitLoss
-8146000
us-gaap Profit Loss
ProfitLoss
-8946000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20904085
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15780863
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20904085
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15201719
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4024000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-4231000
us-gaap Profit Loss
ProfitLoss
-8146000
us-gaap Profit Loss
ProfitLoss
-8946000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-20000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38484000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-27000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4044000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4227000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8173000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8958000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42287000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4024000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
241000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37153000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-4231000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32993000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46120000
us-gaap Profit Loss
ProfitLoss
-8146000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
537000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38484000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6175000
us-gaap Profit Loss
ProfitLoss
-8946000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
125000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35147000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
480000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32993000
us-gaap Profit Loss
ProfitLoss
-8146000
us-gaap Profit Loss
ProfitLoss
-8946000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
209000
us-gaap Share Based Compensation
ShareBasedCompensation
537000
us-gaap Share Based Compensation
ShareBasedCompensation
125000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1140000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-265000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-10000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
246000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-543000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
99000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1979000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-113000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-113000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8510000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10955000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35147000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
480000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35651000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-27000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-12000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24684000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55070000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19025000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46533000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43709000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Onconova Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company’s headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary molecularly targeted agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. The Company believes that the product candidates in its pipeline have the potential to be efficacious in a variety of cancers with unmet medical need. The Company has the following two clinical-stage programs: 1. narazaciclib (ON 123300), a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and 2. rigosertib administered alone or in combination for the treatment of solid tumors. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On May 20, 2021, the Company amended its certificate of incorporation to decrease the number of authorized shares of common stock par value $0.01 per share from 250,000,000 to 125,000,000, and to effect a <span style="-sec-ix-hidden:Hidden_gmt5CBoiik6S6PBxske_Yg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-fifteen</span></span> reverse stock split of its common stock. All common stock, equity, share and per share amounts in the financial statements and notes have been retroactively adjusted to reflect this <span style="-sec-ix-hidden:Hidden_M_nFMCIU1EeQhLvLHql4Pw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-fifteen</span></span> reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has incurred recurring operating losses since inception. For the six months ended June 30, 2022, the Company incurred a net loss of $8,146,000 and as of June 30, 2022 the Company had generated an accumulated deficit of $452,865,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates and its preclinical programs, strategic alliances and its administrative organization. At June 30, 2022, the Company had cash and cash equivalents of $46,533,000. The Company will require substantial additional financing to fund its ongoing clinical trials and operations, and to continue to execute its strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has and may continue to delay, scale-back, or eliminate certain of its research and development activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The Company believes that its cash and cash equivalents will be sufficient to fund its ongoing trials and business operations for more than twelve months from the date of this filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While the Company is not aware of a material impact from the novel coronavirus disease (“COVID-19”) pandemic through June 30, 2022, the full extent to which COVID-19 will directly or indirectly impact the Company’s business, results of operations and financial condition, including manufacturing, clinical trials and research and development costs, depends on future developments that are uncertain at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#843c0c;font-size:1pt;visibility:hidden;">​</span></p>
CY2022Q2 ontx Number Of Clinical Programs In Programs
NumberOfClinicalProgramsInPrograms
2
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
us-gaap Profit Loss
ProfitLoss
-8146000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452865000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46533000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
15000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1342139
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
555228
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
500108
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
500108
CY2022Q2 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1050000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
85000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
253000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
306000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
35000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1472000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000
CY2022Q2 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1968000
CY2021Q4 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1759000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1054000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1217000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
209000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
156000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3231000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3132000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-427000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
209000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
241000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
537000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
125000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Price
SharePrice
8.40
CY2020Q3 ontx Share Based Compensation Arrangement By Share Based Payment Awards Per Share Maximum Value Based On Market Capitalization
ShareBasedCompensationArrangementByShareBasedPaymentAwardsPerShareMaximumValueBasedOnMarketCapitalization
21.60
CY2020Q3 ontx Market Capitalization
MarketCapitalization
250000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11611829
CY2020Q3 us-gaap Share Price
SharePrice
8.40
CY2020Q3 ontx Share Based Compensation Arrangement By Share Based Payment Awards Per Share Maximum Value Based On Market Capitalization
ShareBasedCompensationArrangementByShareBasedPaymentAwardsPerShareMaximumValueBasedOnMarketCapitalization
21.60
CY2020Q3 us-gaap Share Price
SharePrice
8.40
CY2020Q3 ontx Market Capitalization
MarketCapitalization
250000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11611829
CY2021Q1 us-gaap Share Price
SharePrice
22.65
CY2021Q1 ontx Share Based Compensation Arrangement By Share Based Payment Awards Per Share Maximum Value Based On Market Capitalization
ShareBasedCompensationArrangementByShareBasedPaymentAwardsPerShareMaximumValueBasedOnMarketCapitalization
38.10
CY2021Q1 us-gaap Share Price
SharePrice
22.65
CY2021Q1 ontx Market Capitalization
MarketCapitalization
600000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15767492
CY2021Q1 ontx Share Based Compensation Arrangement By Share Based Payment Awards Per Share Maximum Value Based On Market Capitalization
ShareBasedCompensationArrangementByShareBasedPaymentAwardsPerShareMaximumValueBasedOnMarketCapitalization
38.10
CY2021Q1 ontx Market Capitalization
MarketCapitalization
600000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15767492

Files In Submission

Name View Source Status
0001558370-22-013675-index-headers.html Edgar Link pending
0001558370-22-013675-index.html Edgar Link pending
0001558370-22-013675.txt Edgar Link pending
0001558370-22-013675-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R7.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220630.xsd Edgar Link pending
tmb-20220630x10q.htm Edgar Link pending
tmb-20220630xex31d1.htm Edgar Link pending
tmb-20220630xex31d2.htm Edgar Link pending
tmb-20220630xex32d1.htm Edgar Link pending
tmb-20220630xex32d2.htm Edgar Link pending
tmb-20220630_def.xml Edgar Link unprocessable
tmb-20220630_pre.xml Edgar Link unprocessable
tmb-20220630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tmb-20220630_cal.xml Edgar Link unprocessable
tmb-20220630_lab.xml Edgar Link unprocessable